Status:
WITHDRAWN
Combined Ranibizumab and Iluvien for Diabetic Macular Oedema
Lead Sponsor:
Imperial College London
Conditions:
Diabetic Macular Edema
Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This trial investigated whether adding Iluvien sustained release steroid intravitreal eye implant at the beginning of regular anti-VEGF (anti Vascular Endothelial Growth Factor) intravitreal eye injec...
Detailed Description
This study will recruit 58 participants in a double-masked, multi-centre, sham-controlled clinical trial. Participants will receive Iluvien implantation or sham implantation (masked) with a concomitan...
Eligibility Criteria
Inclusion
- General
- Willingness and the ability to provide informed consent.
- Ability and willingness to undertake all scheduled visits, assessment and treatment.
- Age 18 years or above.
- Documented diagnosis of diabetes mellitus (Type I or Type II) as per WHO (World Health Organization) criteria.
- Current regular use of oral anti-hyperglycaemia or insulin therapy.
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \<1% per year during the study duration of 24 months.
- Ocular
- Macular thickening due to Diabetic Macular Oedema (DMO) involving the centre of fovea as measured by Spectral Domain OCT with CRT of at least 400 microns.
- DMO confirmed by clinical examination and fundus fluorescein angiography.
- BCVA between 73 to 25 letters inclusive (Snellen equivalent to 6/12 to 6/96) as measured using ETDRS protocol at 4 meters.
- Pseudophakia in the study eye.
- Adequate ocular media clarity and pupillary dilatation allowing for posterior segment examination and OCT scanning.
Exclusion
- General
- Cerebral vascular accident, transient ischaemic attack or myocardial infarction within 3 months prior to day 1 (baseline).
- Pregnancy or breastfeeding, or intention to become pregnant during the study.
- Participation in an investigational trial involving treatment with any drug or devices within 3 months prior to day 1 (baseline) and must not be enrolled in another investigational trial during their participation in this trial.
- Systemic anti-VEGF-base therapies within 3 months prior to day 1 (baseline).
- Ocular
- History of prior intravitreal anti-VEGF therapy or steroid implant in the study eye.
- History of proliferative diabetic retinopathy.
- History of rubeosis or current rubeosis.
- History of neovascularization, tractional retinal detachment, retinal vein occlusion, or significant pre-retinal fibrosis distorting the macular architecture.
- History of retinal detachment or macular hole stage 3 or above.
- History of vitreoretinal surgery.
- Aphakia.
- History of glaucoma or uncontrolled ocular hypertension.
- Active or suspected ocular or periocular infection or inflammation, including viral diseases of the cornea, conjunctiva and retina, such as active epithelial herpes simplex keratitis (dendritic keratitis), varicella, mycobacterial infections, and fungal diseases.
- Panretinal Photocoagulation (PRP) laser treatment within 3 months prior to day 1.
- Macular laser (focal or grid) within 3 months prior to day 1.
- YAG (yttrium aluminium garnet) laser capsulotomy laser within 3 months prior to day 1.
- Any periocular steroid treatment within 6 months prior to day 1.
- Cataract operation within 3 months prior to day 1.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03784443
Start Date
September 1 2019
End Date
September 1 2023
Last Update
October 2 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.